Harpoon Therapeutics, Inc. Company Profile
News Articles
Harpoon Therapeutics treats first patient in Phase l trial of HPN424
Harpoon Therapeutics has treated the first patient in a Phase l clinical trial to investigate the safety, tolerability and pharmacokinetics...Read More... The post Harpoon Therapeutics treats first pa...
Harpoon Therapeutics Expands Board of Directors
Life Sciences Veteran Scott Myers Appointed to the Board of Directors Harpoon Therapeutics, Inc., an immuno-oncology company developing a new class of T cell engaging t...
Harpoon Therapeutics Announces Appointments to Board of Directors and Management Team
Jonathan Drachman, M.D., former CMO of Seattle Genetics, Brings Immuno-Oncology Expertise to Board Harpoon Therapeutics, Inc., a clinical-stage immuno-oncology company ...
Stand back, Aquaman: Harpoon-throwing satellite takes aim at space junk
Trilobites: Using Harpoon-Like Appendages, Bacteria ‘Fish’ for New DNA
Seeing how microbes snatch new genetic material from their environment could help in the fight against antibiotic resistance.
HPN424, First-in-Class TriTAC™ T Cell Redirection Therapy, Targets Prostate-Specific Membrane Antigen (PSMA) Clinical Data Expected in 2019 Harpoon Therapeut...
Patrick Baeuerle, Ph.D., a pioneer of T cell engaging therapies and executive partner at life sciences venture firm MPM Capital, will give a keynote presentation about next-genera...
Preclinical Data Showcase New T Cell Engaging Platform (TriTAC™) and Lead Drugs, HPN424 and HPN536, Targeting Prostate Cancer and Other Solid Tumors Harpoon Therapeut...
Drugs and Medications
Aldex [Pernix Therapeutics, LLC]
ALDEX GS™ Tablets
Aldex [Pernix Therapeutics, LLC]
ALDEX GS DMTablets
Pro-den rx [Zila Therapeutics, Inc.]
Pro-Den Rx
Pro-den rx [Zila Therapeutics, Inc.]
Pro-Den Rx
Pro-den rx [Zila Therapeutics, Inc.]
Pro-Den Rx
PubMed Articles
The HIV-1 fusion peptide is a target for broadly neutralizing antibodies. In a recent issue of Nature Medicine, Xu et al. (2018) provide proof-of-concept that vaccination with fusion peptide followed...
RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.
Recent developments in intracellular protein delivery.
Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...
RNA-targeted therapeutics for lipid disorders.
To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.
Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...
Clinical Trials
Impact of Ibis on Patients With Advanced COPD
The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...
HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia
Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System
The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...
The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...
This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...
Companies
Harpoon Therapeutics is an immuno-oncology company founded by Patrick Baeuerle, Ph.D., a pioneer in the development of T-cell engaging therapies, and MPM Capital. The company is f...
Maverick Therapeutics is pioneering the next generation of redirected T cell therapeutics in immuno-oncology. Maverickâs highly innovative platform is designed to deliver pot...
Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...
Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...
More Information about "Harpoon Therapeutics, Inc." on BioPortfolio
We have published hundreds of Harpoon Therapeutics, Inc. news stories on BioPortfolio along with dozens of Harpoon Therapeutics, Inc. Clinical Trials and PubMed Articles about Harpoon Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Harpoon Therapeutics, Inc. Companies in our database. You can also find out about relevant Harpoon Therapeutics, Inc. Drugs and Medications on this site too.
